Loading
Total declarations
Companies
▲ Purchases (2 ops.)
▼ Sales (0 ops.)
Latest filing published 13 Feb 2026 for Jade Biosciences, Inc..
Filing timeline
BuySaleBradford D. Dahms
Insider track record
Disclosed buys
2
Disclosed sells
0
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
Bradford D. Dahms: trading record in brief
Bradford D. Dahms (finance chief) discloses dealings in 3 companies, chiefly Theseus Pharmaceuticals, Inc., Cartesian Therapeutics, Inc. and Jade Biosciences, Inc. Between 4 January 2021 and 12 February 2026, the trades on record add up to 5 filings.
Every open-market trade on record is a purchase: 2 purchases worth €27k, and no sale. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Other entries cover 2 share grants.
The latest filing, published on 13 February 2026, reports a share grant in Jade Biosciences, Inc. The last purchase on record was published on 1 December 2022, which is 1,423 days ago. The median gap between a trade and its publication by SEC (Form 4) is 1 day. US insiders must file a Form 4 within two business days of a trade. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Companies and markets linked to Bradford D. Dahms
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations4 total
37,813 shares0Common StockSEC:0001193125-26-052056:0
8,150.225 sharesCommon StockSEC:0001104659-24-023551:0
1,502.189 shares@ US$6.65721.5% of flowCommon StockSEC:0001104659-22-123686:0
Canonical exit: 28 Feb 2023 (T+90)
1,970.036 shares@ US$10.152164.7% of flowCommon StockSEC:0000899243-21-049427:0
Canonical exit: 21 Mar 2022 (T+90)
4 of 4 declarations
